Medical devices, healthcare technology and the business of care
510(k) clearance · K260315

cCeLL - In vivo

VPIX MEDICAL, INC. · Decision date Oct 16, 2026

MEDTECHLEDGER EXPLANATIONK260315

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-16 for cCeLL - In vivo, a traditional 510(k) submitted by VPIX Medical, Inc. of Daejeon, KR, under 510(k) number K260315. The device falls under regulation 882.1480 with classification product code GWG and subsequent product code OWN, in the Neurology specialty and review panel. The application was received 01/30/2026 and was not reviewed by a third party.

SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The record does not describe the device's components, the specific change or comparison to a predicate, or any clinical data, and no summary statement is present in the public information. The page lists no combination product and no authorized predetermined change control plan. Details of the cleared indications and any performance testing remain unknown from this record.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Neurology
Decision date
Oct 16, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260315
Regulatory pathway
510(k) premarket notification
Product code
GWG
Decision code
SESE
Decision date
Oct 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endoscope, Neurological.

Product code
GWG
FDA device class
2

FDA decision timeline

  1. K260315 received

    Application receipt date recorded by FDA.

  2. K260315 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code GWG

Product / regulatory recordCompanyPathwayDecision dateSource
Karl Storz SE & CO. KG510(k) clearanceOct 14, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

VPIX MEDICAL, INC.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Daejeon

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records